Contraceptive Drugs and Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Contraceptive Drugs and Devices Market is segmented by Products (Drugs and Devices), Gender (Male and Female) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Contraceptives Drugs Devices Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.92 %
Contraceptives Drugs Devices Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Contraceptive Drugs and Devices Market is expected to register a CAGR of 7.92% during the forecast period (2022 – 2027).

The outbreak of the COVID-19 pandemic has pushed the healthcare industry into action, with a race to develop both therapeutic and preventive drugs. Exponentially increasing cases of the coronavirus worldwide are leading to the need for the development of novel treatments, with several clinical trials underway. Initially, the global COVID-19 outbreak and the lockdown scenario in various countries have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus. The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of the pandemic. For instance, As per the journal published by the BMJ Publishing Group in May 2022, reported that cases of congenital syphilis, syphilis, and gonorrhea declined in the United States at the beginning of the covid-19 pandemic in 2020, but then the rise in the cases of sexually transmitted diseases has been reported for the remaining year. Similarly, according to United Nations Population Fund, in March 2021, the COVID-19 epidemic disrupted family planning services for an estimated 12 million women, resulting in 1.4 million unplanned pregnancies. In addition to this, during the initial lockdown, women were nine times more likely to have difficulty accessing contraception, resulting in an almost doubling of unexpected births, from 1.3% pre-lockdown to 2.1% post-lockdown. Thus, there is a significant impact on the contraceptive drugs and devices market due to the COVID-19 pandemic.

Certain factors that are propelling the market growth are increasing incidences of sexually transmitted diseases, an increasing rate of unintended pregnancies, and rising government initiatives.

Unwanted pregnancies are becoming more prevalent globally and are a major cause for concern. For instance, according to the United Nations Population Fund, in March 2022, unintended pregnancies accounted for about half of all pregnancies worldwide, with 121 million occurring each year. As per the same source, over 60% of unplanned pregnancies end in abortion, with an estimated 45% of all abortions being unsafe, resulting in 5%–13% of all maternal fatalities, putting the world's capacity to meet the "Sustainable Development Goals" at risk. Additionally, according to the article published in the BMC Pregnancy and Childbirth 2021 by Nebamallika Dahingia, unintended pregnancies affect approximately 85 million women worldwide, with India accounting for more than one in every seven of these cases. In addition, as per the same source, Uttar Pradesh, India's most populous state (population of approximately 200 million), has twice the unwanted fertility rate as compared to the rest of the country. Thus, the rising number of unintended pregnancies is expected to boost the demand for contraceptive drugs and devices which in turn is anticipated to boost the market growth over the forecast period.

In addition, the rising prevalence of sexually transmitted diseases among the population is expected to increase market growth. For instance, according to the report published by the Centers for Disease Control and Prevention in April 2022, it reported that around 133,945 cases of all stages of syphilis were noted, which includes 41,655 cases of primary and secondary syphilis which is considered the most infectious stages of the disease. It also reported an increase of 6.8% in Syphilis during the period 2019 to 2020. The same report also indicated that around 2,148 cases of congenital syphilis were reported in 2020, which includes 149 congenital syphilis-related stillbirths and infant deaths. Additionally, according to the data published by the World Health Organization, in November 2021, it has been observed that around 374 million new infections with one of four sexually transmitted diseases - chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million) and trichomoniasis (156 million) were recorded in 2020. Thus, the rising burden of sexually transmitted diseases is expected to increase the demand for contraception to avoid getting diseases, thereby propelling market growth.

Furthermore, the countries and their governments have recognized the need to curb the increase in unplanned pregnancies and have launched numerous campaigns to educate people and prevent the spread of unplanned pregnancies and abortions. The usage of contraceptive pills is one of them. The fundamental right to privacy guaranteed by the United States Constitution includes the freedom to obtain and use contraceptives. For instance, the United States Agency for International Development (USAID) promotes and supports voluntary family planning and reproductive health initiatives in approximately 40 countries throughout the world. Additionally, in March 2022, National Chlamydia Screening Program (NCSP) was organized in the United Kingdom. The main aim of the program is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time to test results and treatment and re-testing after treatment. The program is also changing from prevention and control to focusing on reducing the harms from untreated chlamydia infection by primarily screening women and girls. Thus, government initiatives are also promoting the use of contraceptive methods to avoid unnecessary births and abortions.

However, the high cost of devices and treatment and side effects associated with the use of contraceptive drugs and devices are some of the factors that are likely to impede market growth over the forecast period.

Scope of the Report

As per the scope of the report, contraception is defined as the intentional prevention of conception through the use of various devices, sexual practices, chemicals, drugs, or surgical procedures to prevent a woman from becoming pregnant and avoid the transmission of sexually transmitted diseases. These devices and drugs function by acting as a physical barrier between the sperm and ovum or by changing the mechanism of ovulation. The Contraceptive Drugs and Devices Market is segmented by Products (Drugs and Devices), Gender (Male and Female), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Products
By Drugs
Oral Contraceptives
Topical Contraceptives
Contraceptive Injectable
By Device
Condoms
Diaphragms
Cervical Caps
Sponges
Vaginal Rings
IUD
Other Devices
By Gender
Male
Female
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Female Segment is Expected to Hold a Major Market Share in the Contraceptive Drugs and Devices Market Over the Forecast Period

The female segment in the contraceptive drugs and devices market is expected to witness significant growth over the forecast period owing to the increased adoption of contraceptive drugs and devices, rising sexually transmitted diseases, and a growing number of unintended pregnancies. 

The rising adoption of contraceptive drugs and devices is the key factor driving the demand for the female contraceptive segment, thereby fueling market growth. For instance, according to an article published by the Journal of Family Medicine and Primary Care, in June 2021, titled “A study on contraceptive prevalence rate and factors influencing it in a rural area of Coimbatore, South India”, the contraceptive prevalence rate was found to be 75%. The most used contraceptive methods were tubectomy (81.6%), intrauterine devices (6.3%), and oral contraceptive pills (0.7%). In addition, as per the same source, the use of contraception was found to be statistically significantly correlated with the women's older age, religion, educational status, socioeconomic status, employment status, number of living children, age at marriage, and age at first childbirth. Similarly, according to an article published by BioMed Central, in January 2020, titled “Exploring young women’s reasons for adopting intrauterine or oral emergency contraception in the United States: a qualitative study”, it has been observed that emergency contraceptive pills and intra-uterine devices are important and acceptable options among women owing to their benefits. Thus, the increasing adoption of contraceptive drugs and devices is expected to propel market growth over the forecast period.

The increasing company focus on adopting various business strategies such as product launches, listing products in the countries, mergers, and company spin-offs are likely to boost the growth of the market over the forecast period. For instance, In January 2022, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Ontario (Ontario Drug Benefit Program), British Columbia (BC PharmaCare), and Nova Scotia (Nova Scotia PharmaCare). Additionally, in November 2021, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Quebec under the Régie de l'assurance Maladie du Québec (RAMQ). Similarly, in June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences is conducting a phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety, and tolerability.

Thus, the above-mentioned factors are expected to boost the growth of the market studied in the country.

Contraceptives Drugs Devices Market : Number of Female Contraceptive Drugs Clinical Trials (in Number), By Phase, Global, As of August 2022

North America Dominates the Market and Expects to do Same Over the Forecast Period

North America is expected to dominate the contraceptive drugs and devices market over the forecast period owing to the factors such as the rising cases of unwanted pregnancies and high abortion rates, the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive drugs and devices, and the rising number of government initiatives.

A large section of the women population represents the reproductive age in the United States as well as Canada. Thus, the rising incidences of unwanted pregnancies and abortion rates are the key factor driving the market growth in the region. For instance, according to the statistics published by Pew Research Center in June 2022, it has been observed that 930,160 abortions were recorded in 2020 in the United States as compared to 916,460 in 2019. Thus, the rising number of abortion cases in the country is expected to increase the demand for adopting various contraceptive methods to avoid unwanted pregnancies, thereby propelling market growth.

In addition, the rising number of sexually transmitted diseases among the population in the region is also contributing to the growth of the market in the region. For instance, In April 2022, a report published by the Centers for Disease Control and Prevention (CDC) titled "Sexually Transmitted Disease Surveillance, 2020" stated that STDs remain a significant public health concern in the United States. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020 with a total of 1,579,885 cases reported to the CDC. In addition, as per the same source, 677,769 different gonorrhea infections were reported in the United States, in 2020. Thus, the rising burden of these diseases among the population is expected to increase the demand for male condoms which protect against pathogens such as gonorrhea, herpes simplex virus (HSV), hepatitis B, HIV, and chlamydia which are expected to propel the market growth in the region over the forecast period.

Furthermore, several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities and enable women and girls to be in control of their contraceptive care.

Moreover, the increasing contraceptive product approval and launches in the region are also expected to boost market growth over the forecast period. For instance, In June 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals launched Estelle under the trademark Nextstellis (drospirenone and estetrol tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action, in the United States. Also, in March 2021, Mithra and Searchlight Pharma received Health Canada approval for Nextstellis, a combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4), in Canada.

Thus, the above-mentioned factors are expected to boost the growth of the market studied in the country.

Contraceptive Drugs and Devices Market - Growth Rate by Region

Competitive Landscape

The Contraceptive Drugs and Devices Market is fragmented competitive and consists of several major players. Over the forecast period, most of the domestic and international players are found focusing on the emerging market and these countries are growing rapidly in the contraceptive drugs and devices market. Some of the companies which are currently dominating the market are Bayer AG, Pfizer Inc., Merck & Co. Inc., Teva Pharmaceuticals Ltd, Agile Therapeutics, Allergan PLC, Ani Pharmaceuticals Inc., Church & Dwight Co. Inc., Fuji Latex Co. Ltd and Johnson & Johnson Ltd.

Major Players

  1. Bayer AG

  2. Teva Pharmaceutical Industries Ltd

  3. Johnson and Johnson

  4. Organon

  5. Pfizer Inc.

Contraceptives Drugs Devices Market Concentration

Recent Development

  • In April 2022, Lupin launched Merzee, (norethindrone acetate and Ethinyl estradiol capsules and ferrous fumarate capsules), a medication to avoid pregnancy in the United States.
  • In February 2022, Mithra and Searchlight Pharma launched Myring, Mithra's vaginal contraceptive ring, under the brand name Haloette in Canada.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of the STDs

      2. 4.2.2 Increasing Rate of Unintended Pregnancies

      3. 4.2.3 Rise in Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Devices and Treatment

      2. 4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 5.1 By Products

      1. 5.1.1 By Drugs

        1. 5.1.1.1 Oral Contraceptives

        2. 5.1.1.2 Topical Contraceptives

        3. 5.1.1.3 Contraceptive Injectable

      2. 5.1.2 By Device

        1. 5.1.2.1 Condoms

        2. 5.1.2.2 Diaphragms

        3. 5.1.2.3 Cervical Caps

        4. 5.1.2.4 Sponges

        5. 5.1.2.5 Vaginal Rings

        6. 5.1.2.6 IUD

        7. 5.1.2.7 Other Devices

    2. 5.2 By Gender

      1. 5.2.1 Male

      2. 5.2.2 Female

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Pfizer Inc.

      3. 6.1.3 Organon

      4. 6.1.4 Teva Pharmaceuticals Ltd

      5. 6.1.5 Agile Therapeutics

      6. 6.1.6 AbbVie (Allergan PLC)

      7. 6.1.7 Ani Pharmaceuticals Inc.

      8. 6.1.8 Church & Dwight Co. Inc.

      9. 6.1.9 Fuji Latex Co. Ltd

      10. 6.1.10 Johnson & Johnson Ltd

      11. 6.1.11 Reckitt Benckiser

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Contraceptive Drugs and Devices Market market is studied from 2019 - 2027.

The Global Contraceptive Drugs and Devices Market is growing at a CAGR of 7.92% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bayer AG, Teva Pharmaceutical Industries Ltd, Johnson and Johnson, Organon, Pfizer Inc. are the major companies operating in Global Contraceptive Drugs and Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!